Remodeling in systolic heart failure: therapeutic implications.
Chatterjee
Kanu
K
Chatterjee Center for Cardiac Research, University of California, San Francisco, USA. chatterj@medicine.ucsf.edu
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D006334:Heart Function Tests; D006801:Humans; D007194:India; D008297:Male; D018570:Risk Assessment; D012720:Severity of Illness Index; D015996:Survival Rate; D013599:Systole / Q000502:physiology; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D020257:Ventricular Remodeling / Q000187:drug effects* / Q000502:physiology*
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents